Premium
IDEAYA Biosciences Inc (IDYA)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including dire... IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Show more
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 SOUTH SAN...
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors PR Newswire SOUTH SAN FRANCISCO, Calif...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 27, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 27, 2024 /PRNewswire/...
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma PR...
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers PR Newswire SOUTH SAN...
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 11, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 11, 2024 /PRNewswire/...
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire SOUTH SAN FRANCISCO...
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 IDE892 is...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.23 | -4.86743173724 | 25.27 | 26.44 | 24.02 | 973377 | 25.569385 | CS |
| 4 | -1.71 | -6.64077669903 | 25.75 | 27.15 | 24.02 | 946690 | 25.48808248 | CS |
| 12 | -6.84 | -22.1502590674 | 30.88 | 32.67 | 24.02 | 950816 | 27.27244638 | CS |
| 26 | -12.71 | -34.5850340136 | 36.75 | 44.42 | 24.02 | 861654 | 31.91406549 | CS |
| 52 | -11.9 | -33.1107401224 | 35.94 | 47.735 | 24.02 | 873140 | 36.38193614 | CS |
| 156 | 6.35 | 35.895986433 | 17.69 | 47.735 | 8.14 | 639046 | 27.73294336 | CS |
| 260 | 15.17 | 171.025930101 | 8.87 | 47.735 | 2.95 | 467060 | 26.02371175 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
